Insights
Search Results
Client Highlights
6.05.26
Wilson Sonsini Advises SewerAI on Strategic Investment
On June 2, 2026, SewerAI, a leading AI platform for sewer and underground infrastructure intelligence, announced a major strategic investment led by JMI Equity, a leading growth equity software investor based in the greater Washington, D.C., area and San Diego, with continued participation from Innovius Capital, Epic Ventures, and Bentley Systems. Wilson Sonsini Goodrich & Rosati advised SewerAI on the transaction.
Client Highlights
6.03.26
Wilson Sonsini Advises Asana on Acquisition of StackAI
On May 28, 2026, Asana, Inc., the operating system for human-agent teams, announced that it has completed the acquisition of StackAI, a no-code AI workflow platform that enables companies to design, test, deploy, and govern custom AI agents and intelligent automation of business-critical workflows. Wilson Sonsini Goodrich & Rosati advised Asana on the transaction.
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Reltio on Acquisition by SAP
On March 27, 2026, SAP, a global leader in enterprise applications and business AI, announced its acquisition of Reltio, a leading master data management (MDM) software provider, to help customers make their SAP and non-SAP enterprise data AI-ready. Terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati advised Reltio on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.19.26
Wilson Sonsini Advises Griptape on Acquisition by Foundry
On February 18, 2026, Foundry, a leading developer of creative software for the media and entertainment industry, announced the completion of its acquisition of Griptape, a pioneer in enterprise-grade AI orchestration. Wilson Sonsini Goodrich & Rosati advised Griptape on the transaction.
As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
12.19.25
Wilson Sonsini Advises Cursor on Acquisition of Graphite
On December 19, 2025, Cursor, the leading AI development platform, announced that it has signed a definitive agreement to acquire Graphite, a start-up that uses AI to review code. The financial terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati advised Cursor on the transaction.
The transaction brings together best-in-class tools for creating, reviewing, and merging code in the AI age. Graphite will continue to operate independently, with the same team and product. According to Cursor, in the coming months the two companies will explore connecting their products, for instance with tighter integrations between local development and pull requests and smarter code review that learns from both systems.
The Wilson Sonsini team that advised Cursor on the transaction included:
M&A
Rich Mullen
Ryan Cooper
Hallee Moore
Valerie Lopez
Drew Downing
The transaction brings together best-in-class tools for creating, reviewing, and merging code in the AI age. Graphite will continue to operate independently, with the same team and product. According to Cursor, in the coming months the two companies will explore connecting their products, for instance with tighter integrations between local development and pull requests and smarter code review that learns from both systems.
The Wilson Sonsini team that advised Cursor on the transaction included:
M&A
Rich Mullen
Ryan Cooper
Hallee Moore
Valerie Lopez
Drew Downing
Client Highlights
12.17.25
Wilson Sonsini Advises Udemy on Combination with Coursera
On December 17, 2025, Udemy, Inc., an AI-powered skills acceleration platform that combines on-demand, multi-language content with real-time innovation, and Coursera, Inc., an AI-powered online learning platform, announced that they have entered into a definitive merger agreement under which Coursera will combine with Udemy in an all-stock transaction. Based on the closing prices of Coursera and Udemy common stock on December 16, 2025, the implied equity value of the combined company is approximately $2.5 billion. The transaction is expected to close by the second half of 2026, subject to the receipt of required regulatory approvals, approval by Coursera and Udemy shareholders, and the satisfaction of other customary closing conditions.
Client Highlights
12.15.25
Wilson Sonsini Advises SpectraWAVE on Acquisition by Philips
On December 15, 2025, Royal Philips announced it has entered into an agreement to acquire Massachusetts-based SpectraWAVE, an innovator in enhanced vascular imaging of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. Wilson Sonsini Goodrich & Rosati is advising SpectraWAVE on the transaction.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.